MannKind

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. 

CEO
Michael E. Castagna
CEOMichael E. Castagna
Employees
592
Employees592
Headquarters
Danbury, Connecticut
HeadquartersDanbury, Connecticut
Founded
1991
Founded1991
Employees
592
Employees592

MNKD Key Statistics

Market cap
1.38B
Market cap1.38B
Price-Earnings ratio
-52.56
Price-Earnings ratio-52.56
Dividend yield
Dividend yield
Average volume
5.17M
Average volume5.17M
High today
$4.14
High today$4.14
Low today
$3.85
Low today$3.85
Open price
$3.93
Open price$3.93
Volume
6.83M
Volume6.83M
52 Week high
$6.51
52 Week high$6.51
52 Week low
$2.23
52 Week low$2.23

Stock Snapshot

The current MannKind(MNKD) stock price is $3.96, with a market capitalization of 1.38B. The stock trades at a price-to-earnings (P/E) ratio of -52.56.

On 2026-08-06, MannKind(MNKD) stock moved within a range of $3.85 to $4.14. With shares now at $3.96, the stock is trading +2.9% above its intraday low and -4.3% below the session's peak.

Trading activity shows a volume of 6.83M, compared to an average daily volume of 5.17M.

Over the past 52 weeks, MannKind(MNKD) stock has traded between a high of $6.51 and a low of $2.23.

Over the past 52 weeks, MannKind(MNKD) stock has traded between a high of $6.51 and a low of $2.23.

MNKD News

TipRanks 9h
MannKind reports Q2 EPS (6c), consensus 2c

Reports Q2 revenue $109.37M, consensus $108.8M. “This was a transformative period for MannKind (MNKD), during which we delivered all three major catalysts we se...

TipRanks 4d
Mannkind Corp. Q4 2025 Earnings Report - Results, Call & Slides - TipRanks

...

Mannkind Corp. Q4 2025 Earnings Report - Results, Call & Slides - TipRanks
Simply Wall St 5d
Why MannKind Is Down 5.3% After Dual Lung And Heart Failure Milestones And What's Next

In late July 2026, MannKind reported positive topline Phase 1b results for its inhaled nintedanib in idiopathic pulmonary fibrosis and secured FDA approval for...

Why MannKind Is Down 5.3% After Dual Lung And Heart Failure Milestones And What's Next

Analyst ratings

88%

of 8 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.